K Malagari, Th Kiakidis, H Moschouris, A Charokopakis, C Vergadis, N Alevisopoulos, V Kartsouni, Ir Panagiotou, O Pellerin, G Glantzounis, D K Filippiadis, E Emmanouil, N Tsavaris, G Psarros, E Delicha, N Kelekis
PURPOSE: To describe safety and clinical outcomes among patients with metastatic colorectal cancer (mCRC) to the liver treated with transarterial chemoembolization with HepaSphere™ Microspheres 30-60 μm loaded with irinotecan (ΙRI-HEP-TACE). MATERIAL AND METHODS: In this prospective study (NCT04866290), 100 adults with confirmed mCRC to the liver who were ineligible for resection were enrolled and followed up to 24 months or death. Study outcomes among Salvage (patients not tolerating more cycles of chemotherapy) and Non-salvage patients included overall survival (OS), progression-free survival (PFS), objective response (OR), objective response rate (ORR), best tumor response (BTR), adverse events (AEs), and pharmacokinetics of irinotecan and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN38)...
June 19, 2023: Cardiovascular and Interventional Radiology